Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Accumulated Expenses (2016 - 2025)

Vycor Medical has reported Accumulated Expenses over the past 16 years, most recently at $89938.0 for Q4 2025.

  • Quarterly Accumulated Expenses fell 42.91% to $89938.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $89938.0 through Dec 2025, down 42.91% year-over-year, with the annual reading at $89938.0 for FY2025, 42.91% down from the prior year.
  • Accumulated Expenses was $89938.0 for Q4 2025 at Vycor Medical, down from $127231.0 in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $544833.0 in Q2 2025 and troughed at $89938.0 in Q4 2025.
  • The 5-year median for Accumulated Expenses is $385539.0 (2021), against an average of $350637.0.
  • Year-over-year, Accumulated Expenses surged 191.14% in 2024 and then tumbled 75.0% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $380479.0 in 2021, then rose by 11.67% to $424897.0 in 2022, then crashed by 53.98% to $195522.0 in 2023, then decreased by 19.42% to $157545.0 in 2024, then tumbled by 42.91% to $89938.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Accumulated Expenses are $89938.0 (Q4 2025), $127231.0 (Q3 2025), and $544833.0 (Q2 2025).